Daniil Gataulin analyst CHARDAN CAPITAL

Currently out of the existing stock ratings of Daniil Gataulin, 104 are a BUY (85.95%), 17 are a HOLD (14.05%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, has had 32.16% of price targets met with an average potential upside of 55.49%, reached in 136 days on average.

Daniil Gataulin has documented 212 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KOD, Kodiak Sciences at 10-May-2026.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on CRVO (CERVOMED).
The best stock recommendation documented was for CRVO (CERVOMED) on 3/13/2025. The price target of $14 was fulfilled within 8 days with a profit of $8.21 (141.8%), with a performance score of 177.25.

Average potential price target upside

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics OTLK OUTLOOK THERAPEUTICS INC FBRX Forte Biosciences CGTX Cognition Therapeutics CRVO CervoMed OCS Oculis Holding AG CLSD Clearside Biomedical MGTX MeiraGTx Holdings PLC OCUL Ocular Therapeutix QURE Uniqure NV TRML Tourmaline Bio ANNX Annexon

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Apr-2024

$5

1 years 1 days ago
(17-Nov-2025)

0/6 (0%)

$0.73 (17.10%)

Buy Since 28-Apr-2020

$5.5

$12

1 years 20 days ago
(29-Oct-2025)

1/8 (12.5%)

$1.27 (30.02%)

366

Hold Since 16-Apr-2025

$4

$5

1 years 21 days ago
(28-Oct-2025)

1/2 (50%)

$-0.26 (-6.10%)

168

Buy Since 18-Jul-2024

1 years 3 months 5 days ago
(13-Aug-2025)

0/2 (0%)

$30.52 (321.94%)

Hold Since 11-Nov-2022

$4

$5

1 years 6 months 3 days ago
(15-May-2025)

4/9 (44.44%)

$1.95 (95.12%)

102

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Daniil Gataulin?

On 2022
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?